Two tbl. in the morning and two tbl. in teh evening until PD

Uveal Melanoma

two tablets in the morning and two in the evening.

Placebo

400 mg Sorafenib bid until PD if staging after Run-In was PR or CR

Sorafenib

400 mg Sorafenib bid until PD if staging after Run-In was SD

Universitätsmedizin Berlin, Charité Campus Benjamin Franklin

Universitätsklinikum Erlangen

Univesitätsklinikum Essen

A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma

A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma

Prof. Dr. med. Max. E. Scheulen

Prof,. Dr. med.

ClinAssess GmbH

The starting dose is 650 mg/m2 per day for 3 continuous days every 2 weeks. In successive courses, infusion time may be increased by 1 day up to 7 days every two weeks and/or drug dose may be increased (650, 1050, 1700 mg/m2/day, etc.). After 4 2-week cycles, cycle length may be extended to 3 or 4 weeks. Treatment continues until evidence of disease progression, intolerable adverse events or withdraw of consent.

Acute Myelocytic Leukemia

Acute Lymphocytic Leukemia

Chronic Myelocytic Leukemia

Chronic Lymphocytic Leukemia

Myelodysplastic Syndromes

The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.

ON 01910.Na

Click here for background information about Mount Sinai School of Medicine.

Click here for background information about ON 01910.Na.

Mount Sinai Medical Center

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS

leukopenia/tyrosine

A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע